0001713210 false Q3 2020 --12-31 0001713210 2020-01-01 2020-09-30 0001713210 2020-11-11 0001713210 2020-09-30 0001713210 2019-12-31 0001713210 2020-07-01 2020-09-30 0001713210 2019-07-01 2019-09-30 0001713210 2019-01-01 2019-09-30 0001713210 us-gaap:CommonStockMember 2018-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001713210 us-gaap:RetainedEarningsMember 2018-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001713210 2018-12-31 0001713210 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001713210 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001713210 2019-01-01 2019-03-31 0001713210 us-gaap:CommonStockMember 2019-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001713210 us-gaap:RetainedEarningsMember 2019-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001713210 2019-03-31 0001713210 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001713210 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001713210 2019-04-01 2019-06-30 0001713210 us-gaap:CommonStockMember 2019-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001713210 us-gaap:RetainedEarningsMember 2019-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001713210 2019-06-30 0001713210 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001713210 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001713210 us-gaap:CommonStockMember 2019-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001713210 us-gaap:RetainedEarningsMember 2019-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001713210 2019-09-30 0001713210 us-gaap:CommonStockMember 2019-12-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001713210 us-gaap:RetainedEarningsMember 2019-12-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001713210 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001713210 2020-01-01 2020-03-31 0001713210 us-gaap:CommonStockMember 2020-03-31 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001713210 us-gaap:RetainedEarningsMember 2020-03-31 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001713210 2020-03-31 0001713210 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001713210 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001713210 2020-04-01 2020-06-30 0001713210 us-gaap:CommonStockMember 2020-06-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001713210 us-gaap:RetainedEarningsMember 2020-06-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001713210 2020-06-30 0001713210 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001713210 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001713210 us-gaap:CommonStockMember 2020-09-30 0001713210 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001713210 us-gaap:RetainedEarningsMember 2020-09-30 0001713210 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001713210 AATP:AgapeATPInternationalHoldingLimitedMember 2020-09-30 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-07 2020-05-08 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-09-30 0001713210 AATP:SubsidiaryCompanyMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyMember 2020-09-30 0001713210 AATP:SubsidiaryCompanyOneMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyOneMember 2020-09-30 0001713210 AATP:SubsidiaryCompanyTwoMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyFourMember 2020-01-01 2020-09-30 0001713210 AATP:SubsidiaryCompanyFourMember 2020-09-30 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember 2020-05-08 0001713210 AATP:ComputerAndOfficeEquipmentMember srt:MinimumMember 2020-01-01 2020-09-30 0001713210 AATP:ComputerAndOfficeEquipmentMember srt:MaximumMember 2020-01-01 2020-09-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2020-01-01 2020-09-30 0001713210 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2020-01-01 2020-09-30 0001713210 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0001713210 AATP:VehicleMember 2020-01-01 2020-09-30 0001713210 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-01-01 2020-09-30 0001713210 2019-01-01 2019-12-31 0001713210 AATP:HealthAndWellnessProductsMember 2020-01-01 2020-09-30 0001713210 AATP:SurvivorSelectMember 2020-07-01 2020-09-30 0001713210 AATP:SurvivorSelectMember 2019-07-01 2019-09-30 0001713210 AATP:SurvivorSelectMember 2020-01-01 2020-09-30 0001713210 AATP:SurvivorSelectMember 2019-01-01 2019-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2020-07-01 2020-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2019-07-01 2019-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2020-01-01 2020-09-30 0001713210 AATP:EnergizedMineralConcentrateMember 2019-01-01 2019-09-30 0001713210 AATP:IonizedCalMagMember 2020-07-01 2020-09-30 0001713210 AATP:IonizedCalMagMember 2019-07-01 2019-09-30 0001713210 AATP:IonizedCalMagMember 2020-01-01 2020-09-30 0001713210 AATP:IonizedCalMagMember 2019-01-01 2019-09-30 0001713210 AATP:OmegaBlendMember 2020-07-01 2020-09-30 0001713210 AATP:OmegaBlendMember 2019-07-01 2019-09-30 0001713210 AATP:OmegaBlendMember 2020-01-01 2020-09-30 0001713210 AATP:OmegaBlendMember 2019-01-01 2019-09-30 0001713210 AATP:BetaMaxxMember 2020-07-01 2020-09-30 0001713210 AATP:BetaMaxxMember 2019-07-01 2019-09-30 0001713210 AATP:BetaMaxxMember 2020-01-01 2020-09-30 0001713210 AATP:BetaMaxxMember 2019-01-01 2019-09-30 0001713210 AATP:VegeFruitFiberMember 2020-07-01 2020-09-30 0001713210 AATP:VegeFruitFiberMember 2019-07-01 2019-09-30 0001713210 AATP:VegeFruitFiberMember 2020-01-01 2020-09-30 0001713210 AATP:VegeFruitFiberMember 2019-01-01 2019-09-30 0001713210 AATP:IronMember 2020-07-01 2020-09-30 0001713210 AATP:IronMember 2019-07-01 2019-09-30 0001713210 AATP:IronMember 2020-01-01 2020-09-30 0001713210 AATP:IronMember 2019-01-01 2019-09-30 0001713210 AATP:YoungFormulaMember 2020-07-01 2020-09-30 0001713210 AATP:YoungFormulaMember 2019-07-01 2019-09-30 0001713210 AATP:YoungFormulaMember 2020-01-01 2020-09-30 0001713210 AATP:YoungFormulaMember 2019-01-01 2019-09-30 0001713210 AATP:OrganicYouthCareCleansingBarMember 2020-07-01 2020-09-30 0001713210 AATP:OrganicYouthCareCleansingBarMember 2019-07-01 2019-09-30 0001713210 AATP:OrganicYouthCareCleansingBarMember 2020-01-01 2020-09-30 0001713210 AATP:OrganicYouthCareCleansingBarMember 2019-01-01 2019-09-30 0001713210 AATP:MitogizeMember 2020-07-01 2020-09-30 0001713210 AATP:MitogizeMember 2019-07-01 2019-09-30 0001713210 AATP:MitogizeMember 2020-01-01 2020-09-30 0001713210 AATP:MitogizeMember 2019-01-01 2019-09-30 0001713210 AATP:NoOneMEDMember 2020-07-01 2020-09-30 0001713210 AATP:NoOneMEDMember 2019-07-01 2019-09-30 0001713210 AATP:NoOneMEDMember 2020-01-01 2020-09-30 0001713210 AATP:NoOneMEDMember 2019-01-01 2019-09-30 0001713210 AATP:EnergetiqueMember 2020-07-01 2020-09-30 0001713210 AATP:EnergetiqueMember 2019-07-01 2019-09-30 0001713210 AATP:EnergetiqueMember 2020-01-01 2020-09-30 0001713210 AATP:EnergetiqueMember 2019-01-01 2019-09-30 0001713210 AATP:TrimPlusMember 2020-07-01 2020-09-30 0001713210 AATP:TrimPlusMember 2019-07-01 2019-09-30 0001713210 AATP:TrimPlusMember 2020-01-01 2020-09-30 0001713210 AATP:TrimPlusMember 2019-01-01 2019-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2020-07-01 2020-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2019-07-01 2019-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2020-01-01 2020-09-30 0001713210 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-09-30 0001713210 AATP:SocialSecurityOrganizationMember 2020-01-01 2020-09-30 0001713210 AATP:SocialSecurityOrganizationMember AATP:MYRCurrencyMember 2020-01-01 2020-09-30 0001713210 AATP:EmployeesProvidentFundMember 2020-01-01 2020-09-30 0001713210 AATP:EmploymentInsuranceSystemMember 2020-01-01 2020-09-30 0001713210 AATP:EmploymentInsuranceSystemMember AATP:MYRCurrencyMember 2020-01-01 2020-09-30 0001713210 AATP:HumanResourceDevelopmentFundMember 2020-01-01 2020-09-30 0001713210 AATP:PeriodEndMYRMember 2020-09-30 0001713210 AATP:PeriodEndMYRMember 2019-12-31 0001713210 AATP:PeriodEndHKDMember 2020-09-30 0001713210 AATP:PeriodEndHKDMember 2019-12-31 0001713210 AATP:MYRCurrencyMember 2020-07-01 2020-09-30 0001713210 AATP:MYRCurrencyMember 2019-07-01 2019-09-30 0001713210 AATP:MYRCurrencyMember 2020-01-01 2020-09-30 0001713210 AATP:MYRCurrencyMember 2019-01-01 2019-09-30 0001713210 AATP:PeriodAverageMYRMember 2020-07-01 2020-09-30 0001713210 AATP:PeriodAverageMYRMember 2019-07-01 2019-09-30 0001713210 AATP:PeriodAverageMYRMember 2020-01-01 2020-09-30 0001713210 AATP:PeriodAverageMYRMember 2019-01-01 2019-09-30 0001713210 AATP:HKDCurrencyMember 2020-07-01 2020-09-30 0001713210 AATP:HKDCurrencyMember 2019-07-01 2019-09-30 0001713210 AATP:HKDCurrencyMember 2020-01-01 2020-09-30 0001713210 AATP:HKDCurrencyMember 2019-01-01 2019-09-30 0001713210 AATP:PeriodAverageHKDMember 2020-07-01 2020-09-30 0001713210 AATP:PeriodAverageHKDMember 2019-07-01 2019-09-30 0001713210 AATP:PeriodAverageHKDMember 2020-01-01 2020-09-30 0001713210 AATP:PeriodAverageHKDMember 2019-01-01 2019-09-30 0001713210 AATP:SubsidiaryCompanyThreeMember 2020-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-07-01 2020-09-30 0001713210 us-gaap:VariableIncomeInterestRateMember 2020-01-01 2020-09-30 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-05-08 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-06-29 2020-07-02 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-01-01 2020-03-31 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-03-31 0001713210 AATP:MrHowKokChoongMember 2020-03-31 0001713210 AATP:ShareExchangeAgreementMember AATP:MrHowKokChoongMember AATP:AgapeSuperiorLivingSdnBhdMember 2020-01-01 2020-09-30 0001713210 srt:MinimumMember 2020-09-30 0001713210 srt:MaximumMember 2020-09-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2020-09-30 0001713210 AATP:ComputerAndOfficeEquipmentMember 2019-12-31 0001713210 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001713210 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001713210 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001713210 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001713210 AATP:VehicleMember 2020-09-30 0001713210 AATP:VehicleMember 2019-12-31 0001713210 AATP:GreenproCapitalCorpMember 2018-05-17 0001713210 AATP:GreenproCapitalCorpMember 2018-10-16 0001713210 srt:DirectorMember 2020-09-30 0001713210 srt:DirectorMember AATP:MYRCurrencyMember 2020-09-30 0001713210 AATP:MrHowKokChoongMember 2020-09-30 0001713210 AATP:UnreservedSdnBhdMember 2020-03-02 0001713210 AATP:MrHowKokChoongMember 2019-12-31 0001713210 AATP:MrHowKokChoongMember 2020-03-31 0001713210 AATP:PhoenixPlusCorpMember 2019-04-03 0001713210 AATP:PhoenixPlusCorpMember us-gaap:CommonStockMember 2019-04-03 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2020-09-30 0001713210 AATP:DirectorsOfUnreservedInvestmentMember 2019-12-31 0001713210 AATP:PhoenixPlusCorpMember 2020-09-30 0001713210 AATP:PhoenixPlusCorpMember 2019-12-31 0001713210 AATP:SeaMember 2020-01-01 2020-09-30 0001713210 AATP:SeaMember 2019-01-01 2019-12-31 0001713210 AATP:SeaMember 2020-09-30 0001713210 AATP:SeaMember 2019-12-31 0001713210 AATP:AgapeATPAsiaLimitedAATPAsiaMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeATPAsiaLimitedAATPAsiaMember 2019-01-01 2019-12-31 0001713210 AATP:AgapeATPAsiaLimitedAATPAsiaMember 2020-09-30 0001713210 AATP:AgapeATPAsiaLimitedAATPAsiaMember 2019-12-31 0001713210 AATP:HostastaySdnBhdMember 2020-01-01 2020-09-30 0001713210 AATP:HostastaySdnBhdMember 2019-01-01 2019-12-31 0001713210 AATP:HostastaySdnBhdMember 2020-09-30 0001713210 AATP:HostastaySdnBhdMember 2019-12-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLOneMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLOneMember 2019-01-01 2019-12-31 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLOneMember 2020-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLOneMember 2019-12-31 0001713210 AATP:MrHowKokChoongMember 2020-01-01 2020-09-30 0001713210 AATP:MrHowKokChoongMember 2019-01-01 2019-12-31 0001713210 AATP:MrHowKokChoongMember 2019-01-01 2019-12-31 0001713210 AATP:MrHowKokChoongMember 2020-09-30 0001713210 AATP:MrHowKokChoongMember 2019-12-31 0001713210 AATP:RedboyPictureSdnBhdRedboyMember 2020-01-01 2020-09-30 0001713210 AATP:RedboyPictureSdnBhdRedboyMember 2019-01-01 2019-12-31 0001713210 AATP:RedboyPictureSdnBhdRedboyMember 2020-09-30 0001713210 AATP:RedboyPictureSdnBhdRedboyMember 2019-12-31 0001713210 AATP:SeaMember 2020-07-01 2020-09-30 0001713210 AATP:SeaMember 2019-07-01 2019-09-30 0001713210 AATP:SeaMember 2019-01-01 2019-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingPtyLtdASLPLMember 2019-01-01 2019-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2020-07-01 2020-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2019-07-01 2019-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2020-01-01 2020-09-30 0001713210 AATP:HostastaySdnBhdOneMember 2019-01-01 2019-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-05-01 2020-05-31 0001713210 AATP:AgapeSuperiorLivingMember 2020-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-06-29 2020-07-31 0001713210 AATP:AgapeSuperiorLivingMember 2020-07-01 2020-09-30 0001713210 country:MY 2020-07-01 2020-09-30 0001713210 country:MY 2019-07-01 2019-09-30 0001713210 country:MY 2020-01-01 2020-09-30 0001713210 country:MY 2019-01-01 2019-09-30 0001713210 country:HK 2020-07-01 2020-09-30 0001713210 country:HK 2019-07-01 2019-09-30 0001713210 country:HK 2020-01-01 2020-09-30 0001713210 country:HK 2019-01-01 2019-09-30 0001713210 country:US 2020-09-30 0001713210 AATP:TwoThousandAndTwentySevenMember country:US 2020-09-30 0001713210 country:US AATP:TwoThousandAndTwentyEightMember 2020-09-30 0001713210 country:US 2020-01-01 2020-09-30 0001713210 country:US AATP:IfUnutilizedMember 2020-01-01 2020-09-30 0001713210 country:US 2019-12-31 0001713210 AATP:LabuanMember 2018-12-28 2019-01-02 0001713210 country:MY 2020-09-30 0001713210 country:MY 2019-12-31 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember srt:MaximumMember 2020-07-01 2020-09-30 0001713210 AATP:NoCustomerMember us-gaap:RevenueFromContractWithCustomerMember srt:MaximumMember 2020-01-01 2020-09-30 0001713210 AATP:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2019-09-30 0001713210 AATP:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember 2019-01-01 2019-09-30 0001713210 us-gaap:AccountsReceivableMember AATP:ECommerceCompanyMember 2020-01-01 2020-09-30 0001713210 AATP:OneCustomersMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001713210 AATP:VendorOneMember 2020-07-01 2020-09-30 0001713210 AATP:VendorTwoMember 2020-07-01 2020-09-30 0001713210 AATP:VendorOneMember 2020-01-01 2020-09-30 0001713210 AATP:VendorTwoMember 2020-01-01 2020-09-30 0001713210 AATP:OneVendorMember us-gaap:AccountsPayableMember 2019-07-01 2019-09-30 0001713210 AATP:OneVendorMember us-gaap:AccountsPayableMember 2019-01-01 2019-09-30 0001713210 AATP:TwoVendorMember us-gaap:AccountsPayableMember 2019-01-01 2019-09-30 0001713210 AATP:OneSalesMember us-gaap:AccountsPayableMember 2020-07-01 2020-09-30 0001713210 AATP:TwoSalesMember us-gaap:AccountsPayableMember 2020-07-01 2020-09-30 0001713210 AATP:NoSalesMember us-gaap:AccountsPayableMember 2020-01-01 2020-09-30 0001713210 AATP:AgapeSuperiorLivingMember 2020-04-02 0001713210 AATP:AgapeSuperiorLivingMember 2020-03-28 2020-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure AATP:RM

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended September 30, 2020

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission File Number 333-220144

 

AGAPE ATP CORPORATION

(Exact name of registrant issuer as specified in its charter)

 

Nevada   36-4838886

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1705 - 1708, Level 17, Tower 2, Faber Tower, Jalan Desa Bahagia,
Taman Desa, 58100 Kuala Lumpur, Malaysia.

(Address of principal executive offices, including zip code)

 

Registrant’s phone number, including area code (60) 192230099

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding twelve months (or shorter period that the registrant was required to submit and post such files).

 

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-accelerated Filer ☒ Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐ No

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

 

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes ☐ No ☐

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at November 11, 2020
Common Stock, $0.0001 par value   376,452,047

 

 

 

 
 

 

TABLE OF CONTENTS

 

      Page
PART I   FINANCIAL INFORMATION  
ITEM 1.   UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:  
    Unaudited Condensed Consolidated Balance Sheets F-1
    Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) F-2
    Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity F-3
    Unaudited Condensed Consolidated Statements of Cash Flows F-4
    Notes to Unaudited Condensed Consolidated Financial Statements F-5 - F-32
ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 3
ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 13
ITEM 4.   CONTROLS AND PROCEDURES 13
PART II   OTHER INFORMATION  
ITEM 1   LEGAL PROCEEDINGS 14
ITEM 2   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 14
ITEM 3   DEFAULTS UPON SENIOR SECURITIES 14
ITEM 4   MINE SAFETY DISCLOSURES 14
ITEM 5   OTHER INFORMATION 14
ITEM 6   EXHIBITS 15
    SIGNATURES 16

 

2
 

 

PART I FINANCIAL INFORMATION

 

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   September 30,  December 31, 
   2020  2019 
        
ASSETS           
CURRENT ASSETS           
Cash and cash equivalents (Included $17,195 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2020)  $3,343,590    $2,744,457 
Accounts receivable   276,799     - 
Accounts receivable – related party   -     520,786 
Amount due from related parties   3,697     2,217 
Inventories   512,784     - 
Prepaid taxes (Included $4,289 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2020)   1,379,890     - 
Prepayments and deposits (Included $3,084 in the consolidated VIE that can be used only to settle obligations of the consolidated VIE as of September 30, 2020)   395,377     269,193 
Prepayments and deposits – related party   1,620     - 
Total Current Assets   5,913,757     3,536,653 
            
OTHER ASSETS           
Property and equipment, net   307,044     - 
Intangible assets, net   6,139     - 
Operating right-of-use assets   417,211     - 
Investment in marketable securities   169,165     66,484 
Investment in non-marketable securities   1,500     732,137 
Deferred offering costs   203,238     - 
Total Other Assets   1,104,297     798,621 
            
TOTAL ASSETS  $7,018,054    $4,335,274 
            
LIABILITIES AND STOCKHOLDERS’ EQUITY           
CURRENT LIABILITIES           
Accounts payable  $-    $2,790 
Customer deposits   373,892     - 
Operating lease liabilities - current   147,180     - 
Other payables and accrued liabilities ($3,110 are included in the consolidated VIE that are without recourse to the credit of Agape ATP Corporation as of September 30, 2020)   464,815     77,246 
Amount due to a related party   962     3,952 
Total Current Liabilities   986,849     83,988 
            
OTHER LIABILITIES           
Operating lease liabilities – non-current  $271,077    $- 
            
TOTAL LIABILITIES   1,257,926     83,988 
            
STOCKHOLDERS’ EQUITY           
Preferred stock, $0.0001 par value; 200,000,000 shares authorized;
None issued and outstanding
   -     - 
Common stock, par value $0.0001; 1,000,000,000 shares authorized, 376,452,047 and 376,275,500 issued and outstanding as of September 30, 2020 and December 31, 2019, respectively   37,645     37,628 
Additional paid in capital   6,440,616     5,293,082 
Accumulated deficit   (818,682)    (1,089,209)
Accumulated other comprehensive income   100,549     9,785 
TOTAL STOCKHOLDERS’ EQUITY   5,760,128     4,251,286 
            
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $7,018,054    $4,335,274 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

   2020   2019   2020   2019 
   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2020   2019   2020   2019 
                 
REVENUE  $1,413,063   $-   $2,923,271   $- 
REVENUE – RELATED PARTY   -    236,736    13,654    1,097,505 
TOTAL REVENUE   1,413,063    236,736    2,936,925    1,097,505 
                     
COST OF REVENUE   (186,891)   (210,383)   (658,445)   (1,027,733)
                     
GROSS PROFIT   1,226,172    26,353    2,278,480    69,772 
                     
SELLING   (159,292)   (338)   (268,648)   (8,184)
COMMISSION   (300,957)   -    (683,455)   - 
GENERAL AND ADMINISTRATIVE   (355,274)   (102,844)   (1,029,052)   (186,622)
TOTAL OPERATING EXPENSES   (815,523)   (103,182)   (1,981,155)   (194,806)
                     
INCOME (LOSS) FROM OPERATIONS   410,649    (76,829)   297,325    (125,034)
                     
OTHER INCOME (EXPENSES)                    
Other income (expenses), net   86,748    (21,235)   62,963    19,219 
Loss from equity investment   -    -    -    (26,085)
Unrealized holding (loss) gain on marketable securities   (24,419)   -    102,247    - 
Gain on deemed disposal of shares in Investee Company   -    -    -    16,509 
Impairment loss in equity investment   -    -    -    (366,834)
TOTAL OTHER INCOME (EXPENSES), NET   62,329    (21,235)   165,210    (357,191)
                     
INCOME (LOSS) BEFORE INCOME TAXES   472,978    (98,064)   462,535    (482,225)
                     
(PROVISION FOR) BENEFIT OF INCOME TAXES   (57,941)   -    (192,008)   6,965 
                     
NET INCOME (LOSS)   415,037    (98,064)   270,527    (475,260)
                     
OTHER COMPREHENSIVE INCOME (LOSS)                    
Foreign currency translation adjustment   54,952    (3,308)   90,764    (2,093)
                     
COMPREHENSIVE INCOME (LOSS)  $469,989   $(101,372)  $361,291   $(477,353)
                     
EARNINGS (LOSS) PER SHARE                    
Basic and diluted  $0.00   $0.00   $0.00   $0.00 
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING                    
Basic and diluted   376,451,896    376,275,500    376,366,198    376,275,500 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF

CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

      Par value  

PAID IN

CAPITAL

   ACCUMULATED DEFICIT  

COMPREHENSIVE

INCOME (LOSS)

   STOCKHOLDERS’ EQUITY 
   COMMON STOCK   ADDITIONAL       ACCUMULATED OTHER   TOTAL 
   Number of shares   Par value  

PAID IN

CAPITAL

   ACCUMULATED DEFICIT  

COMPREHENSIVE

INCOME (LOSS)

   STOCKHOLDERS’ EQUITY 
Balance as of December 31, 2018   376,275,500   $37,628   $5,293,082   $(373,082)  $(1,294)  $4,956,334 
Net income   -    -    -    71,215    -    71,215 
Foreign currency translation adjustment   -    -    -    -    (3,197)   (3,197)
Balance as of March 31, 2019   376,275,500    37,628    5,293,082    (301,867)   (4,491)   5,024,352 
Net loss   -    -    -    (448,411)   -    (448,411)
Foreign currency translation adjustment   -    -    -    -    4,412    4,412 
Balance as of June 30, 2019   376,275,500   $37,628    5,293,082    (750,278)   (79)   4,580,353 
Net loss   -    -    -    (98,064)   -    (98,064)
Foreign currency translation adjustment   -    -    -    -    (3,308)   (3,308)
Balance as of September 30, 2019   376,275,500   $37,628   $5,293,082   $(848,342)  $(3,387)  $(4,478,981)

 

   COMMON STOCK   ADDITIONAL       ACCUMULATED OTHER   TOTAL 
   Number of shares   Par value  

PAID IN

CAPITAL

   ACCUMULATED DEFICIT  

COMPREHENSIVE

INCOME

   STOCKHOLDERS’ EQUITY 
Balance as of December 31, 2019   376,275,500   $37,628   $5,293,082   $(1,089,209)  $9,785   $4,251,286 
Net loss   -    -    -    (231,750)   -    (231,750)
Foreign currency translation adjustment   -    -    -    -    7,770    7,770 
Balance as of March 31, 2020   376,275,500    37,628    5,293,082    (1,320,959)   17,555    4,027,306 
Net income   -    -    -    87,240    -    87,240 
Issuance of common stock in connection with acquisition of Agape Superior Living Sdn Bhd   162,694    16    1,057,492    -    -    1,057,508 
Foreign currency translation adjustment   -    -    -    -    28,042    28,042 
Balance as of June 30, 2020   376,438,194    37,644    6,350,574    (1,233,719)   45,597    5,200,096 
Net income   -    -    -    415,037    -    415,037 
Issuance of common stock in connection with acquisition of Agape Superior Living Sdn Bhd   13,853    1    90,042    -    -    90,043 
Foreign currency translation adjustment   -    -    -    -    54,952    54,952 
Balance as of September 30, 2020   376,452,047   $37,645   $6,440,616   $(818,682)  $100,549   $5,760,128 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

AGAPE ATP CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”)

 

   2020   2019 
  

For the Nine Months Ended

September 30,

 
   2020   2019 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss)  $270,527   $(475,260)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   36,524    - 
Amortization   993    - 
Amortization of operating right-of-use assets   70,047    - 
Loss from equity investment   -    26,085 
Unrealized holding gain on marketable securities   (102,247)   - 
Gain on deemed disposal of shares in investee company   -    (16,509)
Impairment loss in equity investment   -    366,834 
Deferred tax expenses   171,586    - 
Changes in operating assets and liabilities:          
Accounts receivables   (271,876)   - 
Accounts receivables – related party   -    (550,311)
Amount due from a related party   (1,443)   (2,214)
Inventories   132,939    - 
Prepaid taxes   (123,507)   - 
Prepayments and deposits   247,115    148,020 
Prepayments and deposits – related party   (1,619)   - 
Accounts payable   (2,804)   - 
Customer deposits   (1,268,487)   (217,743)
Income taxes payable   -    (6,965)
Other payables and accrued liabilities   167,603    36,391 
Operating lease liabilities   (69,021)   - 
Net cash used in operating activities   (743,670)   (691,672)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   (4,700)   - 
Purchase of intangible assets   (177)   - 
Cash acquired through acquisition of Agape Superior Living Sdn Bhd   1,210,818    - 
Proceeds from sale of non-marketable securities to a related party   70,173    - 
Investment in non-marketable securities   -    (1,500)
Net cash provided by (used in) investing activities   1,276,114    (1,500)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Deferred offering costs   (203,238)   - 
Repayments from related parties   224,342    745 
Amount due to a related party   -    (5,318)
Net cash provided by (used in) financing activities   21,104    (4,573)
           
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS   45,585    (2,092)
           
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   599,133    (699,837)
           
CASH AND CASH EQUIVALENTS, beginning of period   2,744,457    3,452,917 
           
CASH AND CASH EQUIVALENTS, end of period  $3,343,590   $2,753,080 
           
SUPPLEMENTAL CASH FLOWS INFORMATION          
Income taxes paid  $9,101   $- 
Interest paid  $-   $- 
           
SUPPLEMENTAL NON-CASH FLOWS INFORMATION          
Amount transferred from investment in investee company to investment in non-marketable securities  $-   $724,619 
Initial recognition of right-of-use assets and lease liabilities  $479,838   $- 
Sale of non-marketable securities to a related party in exchange for ASL  $656,495   $- 
Issuance of common stock in exchange for acquisition payment of ASL  $1,057,508   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

1. ORGANIZATION AND BUSINESS BACKGROUND

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. (“ASL”) is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. Upon the establishment of WATP, WATP starts collaborating with ASL to carry out its Wellness programs.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

The accompanying unaudited condensed consolidated financial statements reflect the activities of the Company, Agape ATP Corporation (“AATP LB”), Agape ATP International Holding Limited (“AATP HK”), Wellness ATP International Holdings Sdn, Bhd. (“Wellness ATP”), ASL and its variable interest entity (“VIE”), Agape S.E.A. Sdn. Bhd. (“SEA”) (See Note 3).

 

Details of the Company’s subsidiaries:

 

   

Subsidiary company

name

 

Place and

date of

incorporation

  Particulars of issued capital  Principal activities 

Proportional of ownership

interest and

voting power

held

 
                  
 1.    Agape ATP Corporation  Labuan,
March 6, 2017
  100 shares of ordinary share of US$1 each  Investment holding   100%
                    
 2.    Agape ATP International Holding Limited  Hong Kong,
June 1, 2017
  1,000,000 shares of ordinary share of HK$1 each  Wholesaling of health and wellness products; and health solution advisory services   100%
                    
 3.   Agape Superior Living Sdn. Bhd.  Malaysia,
August 8, 2003
  9,590,598 shares of ordinary share of RM1 each  Health and wellness products and health solution advisory services via network marketing   99.99%
                    
 4.   Agape S.E.A. Sdn. Bhd.  Malaysia,
March 4, 2004
  2 shares of ordinary share of RM1 each  VIE of Agape Superior Living Sdn. Bhd.   VIE 
                    
 5.   Wellness ATP International Holdings Sdn, Bhd  Malaysia,
September 11, 2020
  100 shares of ordinary share of RM1 each  The promotion of wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns   100%

 

F-5

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

Business Overview

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

The Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), and include all normal and recurring adjustments that management of the Company considers necessary for a fair presentation of its financial position and operation results. Interim results are not necessarily indicative of results to be expected for any other interim period or for the full year. The information included in this Form 10-Q should be read in conjunction with information included in the Company’s transition report on Form 10-K for the period ended December 31, 2019, filed with the Securities and Exchange Commission on March 27, 2020.

 

F-6

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Principles of consolidation

 

The unaudited condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and its VIE over which the Company exercises control and, where applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company, its subsidiaries and its VIE have been eliminated upon consolidation.

 

Subsidiaries are those entities in which the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes at the meeting of directors.

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE.

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

Cash and cash equivalents are carried at cost and represent cash on hand, time deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less.

 

Accounts receivable and accounts receivable – related party

 

Accounts receivable and accounts receivable – related party are recorded at the invoiced amount less an allowance for any uncollectible accounts and do not bear interest, which are due on credit term. Accounts receivable also include money due from a third-party e-commerce platform acting as a collection agent for the Company on the sales through their platform. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of September 30, 2020, and December 31, 2019, no valuation allowance was recorded.

F-7

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Inventories

 

Inventories consist of finished goods and are stated at the lower of cost or net realizable value using the first-in first-out method.

 

Prepaid taxes

 

Prepaid taxes include (i) prepaid income taxes that will either be refundable or utilized to offset future income tax; and (ii) goods and service tax (“GST”) to be refundable.

 

Prepayments and deposits

 

Prepayments and deposits are mainly cash deposited or advanced to suppliers for future inventory purchases or service providers for future services. This amount is refundable and bears no interest. For any prepayments and deposits determined by management that such advances will not be in receipts of inventories, services, or refundable, the Company will recognize an allowance account to reserve such balances. Management reviews its prepayments and deposits on a regular basis to determine if the allowance is adequate, and adjusts the allowance when necessary. Delinquent account balances are written-off against allowance for doubtful accounts after management has determined that the likelihood of collection is not probable. The Company’s management continues to evaluate the reasonableness of the valuation allowance policy and update it if necessary. As of September 30, 2020, and December 31, 2019, there is no allowance for the doubtful accounts.

 

Property and equipment, net

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets with no residual value. The estimated useful lives are as follows:

 

   Useful Life
    
Computer and office equipment  5-7 years
Furniture & fixtures  6-7 years
Leasehold improvements  Lease Term
Vehicle  5 years

 

The cost and related accumulated depreciation of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements of income and comprehensive income. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions, renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.

 

F-8

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Intangible assets, net

 

Intangible assets, net, are stated at cost, less accumulated amortization. Amortization expense is recognized on the straight-line basis over the estimated useful lives of the assets as follows:

 

Classification  Useful Life
    
Computer software  5 years

 

Impairment for long-lived assets

 

Long-lived assets, including property and equipment, and intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset. If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on a discounted cash flows approach or, when available and appropriate, to comparable market values. As of September 30, 2020, and December 31, 2019, no impairment of long-lived assets was recognized.

 

Deferred offering costs

 

Deferred offering costs represents costs associated with the Company’s current offering which will be netted against the proceeds from the Company’s current offering.

 

Investment in marketable equity securities

 

Prior to July 1, 2019, marketable securities included in investment in marketable equity securities (non-current) are stated at the lower of cost or market in the aggregate. Other marketable securities (non-current) are stated at the lower of cost or market in the aggregate and investments other than marketable equity securities in other investments (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Investments in marketable equity securities (non-current) are reported at fair value with changes in fair value recognized in the Company’s consolidated statements of operations and comprehensive loss in the caption of “unrealized holding losses on marketable securities” in each reporting period.

 

F-9

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Investment in non-marketable equity securities

 

Prior to July 1, 2019, investments in non-marketable equity securities (non-current) are stated at cost less any significant decline in fair value assessed to be other than temporary. Realized gains and losses on the sale of securities are based on the average cost of all the units of a particular security held at the time of sale.

 

On July 1, 2019, the Company adopted ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Due to the Company’s non-marketable equity securities (non-current) does not qualify for the practical expedient to estimate fair value in accordance with ASC 820-10-35-59, the Company has selected to record its investments in non-marketable equity securities (non-current) at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issue.

 

At each reporting period, the Company will make a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. The qualitative assessment indicators include, but are not limited to: (1) A significant deterioration in the earnings performance, credit rating, asset quality, or business prospects of the investee; (ii) A significant adverse change in the regulatory, economic, or technological environment of the investee; (iii) A significant adverse change in the general market condition of either the geographical area or the industry in which the investee operates; (iv) A bona fide offer to purchase, an offer by the investee to sell, or a completed auction process for the same or similar investment for an amount less than the carrying amount of that investment; and (v) Factors that raise significant concerns about the investee’s ability to continue as a going concern, such as negative cash flows from operations, working capital deficiencies, or noncompliance with statutory capital requirements or debt covenants. If the qualitative assessment indicators indicated that the non-marketable equity securities (non-current) is deemed to be impaired, the Company would recognize the impairment loss equal to the difference between the fair value of the investment and its carrying amount.

 

Customer deposits

 

Customer deposits represent amounts advanced by customers on product orders and discounted value of unapplied coupons. Customer deposits are reduced when the related sale is recognized in accordance with the Company’s revenue recognition policy.

 

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

F-10

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019 Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

F-11

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilize the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues. For the three and nine months ended September 30, 2020, the Company recognized $93,322 and $156,499 as forfeited coupon income.

 

As of September 30, 2020, the Company had contracts for the sales of health and wellness products amounting to $271,173 which it is expected to fulfill within 12 months from September 30, 2020.

 

Disaggregated information of revenues by products are as follows:

 

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2020   2019   2020   2019 
                 
Survivor Select  $83,107   $-   $119,101   $- 
Energized Mineral Concentrate   58,491    100,065    81,097    238,546 
Ionized Cal-Mag   352,718    25    850,716    55,685 
Omega Blend   109,258    68,774    271,801    - 
BetaMaxx   123,080    67,663    134,514    91,133 
Vege Fruit Fiber   1,814    -    7,920    - 
Iron   22,581    -    135,743    - 
Young Formula   378,970    52    728,708    117,384 
Organic Youth Care Cleansing Bar   12,395    8    41,200    17,736 
Mitogize   36,914    -    41,625    - 
No. 1 MED   33,379    62    41,799    140,650 
Energetique   75,425    -    134,273    - 
Trim+   124,931    87    348,428    198,701 
Total revenues  $1,413,063   $236,736   $2,936,925   $1,097,505 

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers.

 

F-12

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three and nine months ended September 30, 2020, revenues from health and wellness services are immaterial to the Company’s unaudited condensed consolidated statements of operations and comprehensive income (loss).

 

Cost of revenue

 

Cost of revenue includes freight-in and the purchase cost of manufactured goods for sale to customers.

 

Shipping and handling

 

Shipping and handling charges amounted to $3,467 and $0 for the three months ended September 30, 2020 and 2019, respectively. Shipping and handling charges amounted to $6,022 and $0 for the nine months ended September 30, 2020 and 2019, respectively. Shipping and handling charges are expensed as incurred and included in selling expenses.

 

Advertising costs

 

Advertising costs amounted to $5,634 and $0 for the three months ended September 30, 2020 and 2019, respectively. Advertising costs amounted to $8,516 and $0 for the nine months ended September 30, 2020 and 2019, respectively. Advertising costs are expensed as incurred and included in selling expenses.

 

Commission expenses

 

Commission expenses are the Company’s most significant expenses. As with all companies in the network marketing industry, the Company’s sales channel is external to the Company. The Company’s “external sales force” is stratified into two levels based on priority recruitment. First, there are sales distributors. Second, all members recruited by a sales distributor, directly or indirectly, are referred to as “sales network members”. The Company pays commission to every sales distributor based on purchases made by its sales network members which includes the independent direct sales members. Top performing distributors with their own physical stores may also become stockists of the Company, whereby they enjoy benefits such as maintaining a certain amount of the Company’s inventory on their store premises. The stockists shall account to the Company for all products sales from their store premises as monitored through the Company’s centralized stock tracking system. The Company pays a separate commission to stockists based on revenue generated from the stockists’ physical stores. Commission expenses amounted to $300,957 and $0 for the three months ended September 30, 2020 and 2019, respectively. Commission expenses amounted to $683,455 and $0 for the nine months ended September 30, 2020 and 2019, respectively.

 

Defined contribution plan

 

The full-time employees of the Company are entitled to the government mandated defined contribution plan. The Company is required to accrue and pay for these benefits based on certain percentages of the employees’ respective salaries, subject to certain ceilings, in accordance with the relevant government regulations, and make cash contributions to the government mandated defined contribution plan. Total expenses for the plans were $25,442 and $0 for the three months ended September 30, 2020 and 2019, respectively. Total expenses for the plans were $49,152 and $0 for the nine months ended September 30, 2020 and 2019, respectively.

 

F-13

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

The related contribution plans include:

 

  - Social Security Organization (“SOSCO”) – 1.75% based on employee’s monthly salary capped of RM 4,000;
  - Employees Provident Fund (“EPF”) – 12% based on employee’s monthly salary;
  - Employment Insurance System (“EIS”) – 0.2% based on employee’s monthly salary capped of RM 4,000;
  - Human Resource Development Fund (“HRDF”) – 1% based on employee’s monthly salary

 

Income taxes

 

The Company accounts for income taxes in accordance with U.S. GAAP for income taxes. The charge for taxation is based on the results for the fiscal year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

 

Deferred taxes is accounted for using the asset and liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized. Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Current income taxes are provided for in accordance with the laws of the relevant taxing authorities.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. No penalties and interest incurred related to underpayment of income tax for the three and nine months ended September 30, 2020 and 2019.

 

The Company conducts much of its business activities in Hong Kong and Malaysia and is subject to tax in each of their jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

 

Comprehensive income (loss)

 

Comprehensive income (loss) consists of two components, net income (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenue, expenses, gains and losses that under GAAP are recorded as an element of stockholders’ equity but are excluded from net income. Other comprehensive income (loss) consists of a foreign currency translation adjustment resulting from the Company not using the U.S. dollar as its functional currencies.

 

F-14

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Non-controlling interest

 

Non-controlling interest mainly consists of approximately 0.01% (2 ordinary shares out of 9,590,598 shares) of the equity interests of ASL held by two individuals. The non-controlling interests are presented in the consolidated balance sheets, separately from equity attributable to the shareholders of the Company. Non-controlling interests in the results of the Company are presented on the face of the consolidated statements of operations as an allocation of the total income or loss for the periods between non-controlling interest holders and the shareholders of the Company. As of September 30, 2020, the non-controlling interest balance was $0 and therefore not presented in the accompanying unaudited condensed consolidated financial statements.

 

Earnings (loss) per share

 

The Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, “Earnings per Share”. ASC 260 requires companies to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average ordinary share outstanding for the period. Diluted EPS presents the dilutive effect on a per share basis of the potential ordinary shares (e.g., convertible securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential ordinary shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. For the three and nine months ended September 30, 2020 and 2019, there were no dilutive shares.

 

Foreign currencies translation and transaction

 

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).

 

The reporting currency of the Company is United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. The Company’s subsidiary in Labuan maintains its books and record in United States Dollars (“US$”) albeit its functional currency being the primary currency of the economic environment in which the entity operates, which is the Malaysian Ringgit (“MYR” or “RM”). The Company’s subsidiary in Hong Kong maintains its books and record in Hong Kong Dollars (“HK$”), similar to its functional currency. The Company’s subsidiary and VIE in Malaysia conducts its businesses and maintains its books and record in the local currency, Malaysian Ringgit (“MYR” or “RM”), as its functional currency.

 

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income within the statements of stockholders’ equity. Cash flows are also translated at average translation rates for the periods, therefore, amounts reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

 

F-15

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Translation of foreign currencies into US$1 have been made at the following exchange rates for the respective periods:

 

 

   As of 
   September 30, 2020   December 31, 2019 
         
Period-end MYR : US$1 exchange rate   4.16    4.09 
Period-end HKD : US$1 exchange rate   7.75    7.79 

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2020   2019   2020   2019 
                 
Period-average MYR : US$1 exchange rate   4.20    4.18    4.23    4.13 
Period-average HKD : US$1 exchange rate   7.75    7.84    7.76    7.84 

 

Related parties

 

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

F-16

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Leases

 

Effective July 1, 2019, the Company adopted ASU 2016-02, “Leases” (Topic 842), and elected the practical expedients that does not require the Company to reassess: (1) whether any expired or existing contracts are, or contain, leases, (2) lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company also adopted the practical expedient that allows lessees to treat the lease and non-lease components of a lease as a single lease component. There is no impact from the adoption of ASC 842 as of July 1, 2019, as the Company did not have any existing leases with a lease term in excess of twelve months on July 1, 2019.

 

Operating lease right-of-use (“ROU”) assets and lease liabilities are recognized at the adoption date of July 1, 2019 or the commencement date, whichever is earlier, based on the present value of lease payments over the lease term. Since the implicit rate for the Company’s leases is not readily determinable, the Company use its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term.

 

Lease terms used to calculate the present value of lease payments generally do not include any options to extend, renew, or terminate the lease, as the Company does not have reasonable certainty at lease inception that these options will be exercised. The Company generally considers the economic life of its operating lease ROU assets to be comparable to the useful life of similar owned assets. The Company has elected the short-term lease exception, therefore operating lease ROU assets and liabilities do not include leases with a lease term of twelve months or less. Its leases generally do not provide a residual guarantee. The operating lease ROU asset also excludes lease incentives. Lease expense is recognized on a straight-line basis over the lease term.

 

The Company reviews the impairment of its ROU assets consistent with the approach applied for its other long-lived assets. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on its ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company has elected to include the carrying amount of operating lease liabilities in any tested asset group and includes the associated operating lease payments in the undiscounted future pre-tax cash flows.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit

 

F-17

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its unaudited condensed consolidated financial statements.

 

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current period presentation for the three and nine months ended September 30, 2019. These reclassifications have no effect on the unaudited condensed consolidated statements of operations and comprehensive income (loss).

 

3. VARIABLE INTEREST ENTITY (“VIE”)

 

SEA is a trading company incorporated on March 4, 2004, under the laws of Malaysia. SEA provided all of ASL’s purchases. Its equity at risk was insufficient to finance its activities and 100% of its business is transacted with ASL. Therefore it was considered to be a VIE and ASL is the primary beneficiary since it has both of the following characteristics:

 

  a. The power to direct the activities of the VIE that most significantly impact the VIE’s economic performance; and
  b. The obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

F-18

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

3. VARIABLE INTEREST ENTITY (“VIE”) (Continued)

 

Accordingly, the accounts of SEA is consolidated in the accompanying unaudited condensed financial statements.

 

The carrying amount of the VIE’s assets and liabilities were as follows:

 

   September 30, 2020 
     
Current assets  $209,118 
Current liabilities   (216,789)
Net deficit  $(7,671)

 

   September 30, 2020 
Current asset:     
Cash and cash equivalents  $17,195 
Accounts receivable – intercompany   184,550 
Prepaid taxes   4,289 
Prepayments and deposits   3,084 
Total current assets   209,118 
      
Current liabilities:     
Accounts payable – intercompany  $213,318 
Other payables and accrued liabilities   3,110 
Other payables – intercompany   361 
Total current liabilities  $216,789 

 

The summarized operating results of the VIE’s are as follows:

 

   For the Three
Months Ended
September 30, 2020
  

For the Nine
Months Ended
September 30, 2020

 
         
Operating revenues  $146,788   $276,280 
Gross profit  $955   $2,328 
Loss from operations  $(4,171)  $(7,920)
Net loss  $(8,627)  $(26,766)

 

F-19

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

4. BUSNINESS COMBINATION

 

On May 8, 2020, the Company entered into a Share Exchange Agreement (“SPA”) with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in ASL, an entity incorporated in Malaysia. Pursuant to the SPA, as amended on July 1, 2020, Mr. How will receive an aggregate consideration of $1,804,046, which was determined based on the net asset carrying value of ASL as at March 31, 2020. The aggregate consideration shall be satisfied by (i) the offset of the Consideration whereby the Company has a loan receivable of $656,495 as of March 31, 2020 due from Mr. How; and (ii) allotment and issuance of common stock of the Company. The Company shall allot and issue 176,547 shares of the Company’s common stock, par value $0.0001, representing approximately 0.0469% of the total issued and outstanding shares in the Company after the issuance of the Shares, which is valued at $1,147,551 based on the closing price of $6.50 of the Company as quoted on the OTC Market on March 31, 2020. As of September 30, 2020, the Company has issued all 176,547 shares of the Company’s common stock.

 

The Company’s acquisition of ASL was accounted for as a business combination in accordance with ASC 805. The Company has allocated the purchase price of ASL based upon the carrying value of the identifiable assets acquired and liabilities assumed on April 1, 2020 as ASL was under the common control of Mr. How.

 

The following table summarizes the carry value of the identifiable assets acquired and liabilities assumed on the acquisition date, which represents the net purchase price allocation on the date of the acquisition of ASL.

 

   Carry Value 
ASSETS     
Current assets     
Cash  $1,206,493 
Other receivables   33,210 
Other receivables - related parties   219,121 
Inventories   616,880 
Prepaid taxes   1,206,821 
Prepayments and other assets   318,267 
Total current assets   3,600,792 
      
Other assets     
Property and equipment, net   325,648 
Intangible assets, net   6,686 
Deferred taxes asset, net   172,250 
Total other assets   504,584 
      
Total assets  $4,105,376 
      
LIABILITIES AND SHAREHOLDERS’ EQUITY     
Current liabilities     
Accounts payable - related party  $491,628 
Customer deposits   1,600,606 
Other payables and accrued liabilities   209,096 
Total current liabilities   2,301,330 
      
Total liabilities   2,301,330 
      
Total net assets acquired   1,804,046 

 

F-20

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

4. BUSNINESS COMBINATION (Continued)

 

The following unaudited pro forma combined results of operations presents the Company’s financial results as if the acquisition of ASL had been completed on January 1, 2019. The unaudited pro forma results do not reflect operating efficiencies or potential cost savings which may result from the consolidation of operations. Accordingly, the unaudited pro forma financial information is not necessarily indicative of the results of operations that the Company would have recognized had we completed the transaction on January 1, 2019. Future results may vary significantly from the results in this pro forma information because of future events and transactions, as well as other factors.

 

   For the Three Months Ended   For the Nine Months Ended   For the Nine Months Ended 
   September 30, 2019   September 30, 2020   September 30, 2019 
Revenue  $946,912   $4,178,177   $2,861,274 
Cost of revenue   (111,472)   (737,512)   (421,471)
Gross profit   835,440    3,440,665    2,439,803 
Total operating expenses   (880,362)   (3,025,438)   (3,493,377)
Income (loss) from operations   (44,922)   415,227    (1,053,574)
Other income (expense), net   (86,515)   75,603    (324,170)
Income (loss) before income taxes   (131,437)   490,830    (1,377,744)
Benefit of (Provision for) income taxes   4,966    (242,841)   207,146 
Net income (loss)  $(126,471)  $247,989   $(1,170,598)
Net income (loss) per common share - basic and diluted   0.00    0.00    0.00 
Weighted average number of common shares outstanding - basic and diluted  $376,452,047   $376,452,047   $376,452,047 

 

5. CASH AND CASH EQUIVALENTS

 

As of September 30, 2020 and December 31, 2019 the Company has $3,343,590 and $2,744,457, respectively, of cash and cash equivalents, which consists of $756,707 and $238,937, respectively, of cash in banks and $2,564,672 and $2,505,520, respectively, of time deposits placed with banks or other financial institutions and are all highly liquid investments with an original maturity of three months or less. The effective interest rate for the time deposits ranges between 2.95% to 3.25% per annum.

 

F-21

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

6. ACCOUNTS RECEIVABLE AND ACCOUNTS RECEIVABLE – RELATED PARTY

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
Accounts receivable  $276,799   $- 
Accounts receivable – related party   -    520,786 
Allowance for doubtful accounts   -    - 
Total accounts receivable and accounts receivable – related party  $276,799   $520,786 

 

7. INVENTORIES

 

Inventories consist of the following:

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
Finished goods  $512,784   $- 

 

8. PREPAYMENTS AND DEPOSITS

 

   As of
September 30, 2020
   As of
December 31, 2019
 
Prepaid expenses  $3,084   $2,641 
Receivables from sales distributors   33,509    - 
Deposits to suppliers   358,784    266,552 
Total prepaid expenses and deposits  $395,377   $269,193 

 

9. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consist of the following:

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
Computer and office equipment  $78,685   $- 
Furniture & fixtures   122,675    - 
Leasehold improvements   203,384    - 
Vehicle   99,099    - 
Subtotal   503,843    - 
Less: accumulated depreciation   (196,799)   - 
Total  $307,044   $- 

 

Depreciation expense for the three months ended September 30, 2020 and 2019 amounted to $18,808 and $0, respectively. Depreciation expense for the nine months ended September 30, 2020 and 2019 amounted to $36,524 and $0, respectively.

 

F-22

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

10. INTANGIBLE ASSETS, NET

 

Intangible assets, net, consist of the following:

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
         
Computer software  $34,591   $    - 
Less: accumulated amortization   (28,452)   - 
Total  $6,139   $- 

 

Amortization expense for the three months ended September 30, 2020 and 2019 amounted to $511 and $0, respectively. Amortization expense for the nine months ended September 30, 2020 and 2019 amounted to $993 and $0, respectively.

 

11. INVESTMENT IN MARKETABLE SECURITIES

 

  (i) On May 17, 2018, the Company purchased 83,333 shares of common stock in Greenpro Capital Corp. for $500,000 at a purchase price of $6 per share.
     
  (ii) On October 16, 2018, the Company purchased 33,333 shares of common stock in Greenpro Capital Corp. for $1,000 at a purchase price of $0.03 per share.

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
Cost of investment  $66,484   $134,166 
Unrealized holding gain (loss)   102,247    (68,391)
Exchange rate effect   434    709 
Investment in marketable securities  $169,165   $66,484 

 

12. INVESTMENT IN NON-MARKETABLE SECURITIES

 

The Company invested in Unreserved Sdn Bhd with the investment amount of $863,592 (RM 3,500,000), which approximated 20% of the equity interest of Unreserved Sdn Bhd and is accounted for under the equity method of accounting. On March 10, 2019 Unreserved Sdn Bhd issued additional common stock for working capital. As the Company did not subscribe for the additional common stock, the Company’s equity interest in investee company was diluted from approximately 20.0% to approximately 17.86%. Effective from March 10, 2019, the Company discontinued equity accounting on the investee company. The Company also ceased control over the operations of the investee company on the same date. Accordingly, the investment in investee company was reclassified to investment in non-marketable securities.

 

Unreserved Sdn Bhd was incorporated in Malaysia with 2,500,000 ordinary shares authorized, issued and outstanding. Mr. Lim Hun Soon @ David Lim and Ms. Aniza Helina Akmi Karim are the directors of Unreserved Sdn Bhd. Mr. How Kok Choong was a director of the company from April 30, 2018 to March 27, 2019.

 

F-23

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

12. INVESTMENT IN NON-MARKETABLE SECURITIES (Continued)

 

On March 2, 2020, the Company agreed to sell the 17.86% ownership interest in Unreserved Sdn Bhd at the December 31, 2019 carrying value of $730,637 to Mr. How Kok Choong, the CEO and director of the Company. The Company received proceeds of $70,173, and had an amount due from director of $660,464 at March 31, 2020. In May 2020, the entire outstanding balance was settled as part of the consideration in a transaction which the Company had acquired the CEO’s ownership interest of Agape Superior Living Sdn. Bhd.

 

On April 3, 2019, the Company purchased a 5% of stock or 15,000,000 shares of common stock in Phoenix Plus Corp. for $1,500 at purchase price of $0.0001 per share.

 

Unreserved Sdn Bhd  As of
September 30, 2020
   As of
December 31, 2019
 
Investment in non-marketable securities  $730,637   $730,637 
Less: Sale of investment in non-marketable securities   (730,637)   - 
Investment in non-marketable securities  $-   $730,637 
           
Phoenix Plus Corporation          
Cost of investment  $1,500   $1,500 
           
Total investment in non-marketable securities  $1,500   $732,137 

 

13. OTHER PAYABLES AND ACCRUED LIABILITIES

 

  

As of

September 30, 2020

  


As of

December 31, 2019

 
Accrued professional fees  $147,892   $58,594 
Accrued promotion expenses   36,169    - 
Accrued payroll   24,215    - 
Accrued bonus   177,749    - 
Others   78,791    18,652 
Total other payables and accrued liabilities  $464,816   $77,246 

 

F-24

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Related party balances

 

Accounts receivable – related party

 

Name of Related Party  Relationship  Nature 

As of

September 30, 2020

  

As of

December 31, 2019

 
               
SEA  VIE of ASL, Mr. How Kok Choong, the CEO and director of the Company is the sole shareholder and director of SEA  Sales of products  $-   $520,786 
Total        $-   $520,786 

 

Amount due from related parties

 

Name of Related Party   Relationship   Nature  

As of

September 30, 2020

    As of
December 31, 2019
 
                         
Agape ATP (Asia) Limited (“AATP Asia”)   Mr. How Kok Choong, the CEO and director of the Company is also the sole shareholder and director of AATP Asia   Expenses paid for AATP Asia   $ 2,228     $ 2,217  
Hostastay Sdn. Bhd.   Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay   Sublease rent due from Hostastay     1,469       -  
Total           $ 3,697     $ 2,217  

 

Prepayments and Deposits - related party

 

Name of Related Party   Relationship   Nature  

As of

September 30, 2020

    As of
December 31, 2019
 
                         
Agape Superior Living Pty Ltd (“ASLPL”)   Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of ASLPL   Prepayment for Printing Label   $ 1,620     $  -  
Total           $ 1,620     $ -  

 

F-25

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

14. RELATED PARTY BALANCES AND TRANSACTIONS (Continued)

 

Amount due to a Related Party

 

Name of Related Party   Relationship   Nature  

As of

September 30, 2020

    As of
December 31, 2019
 
                         
Mr. How Kok Choong   CEO and director of the Company   Acquisition payment of ASL and expenses paid for the Company   $ -     $ 3,952  
Redboy Picture Sdn Bhd “Redboy”   Mr. How Kok Choong, the CEO and director of the Company is also the director of Redboy   Amount due to Redboy for business operational fees     962       -  
Total           $ 962     $ 3,952  

 

Related party transactions

 

Revenue

 

Name of Related Party  Relationship  Nature 

For the Three Months Ended

September 30, 2020

  

For the Three Months Ended

September 30, 2019

 
               
SEA  VIE of ASL, Mr. How Kok Choong, the CEO and director of the Company is the sole shareholder and director of SEA  Sales of products  $-   $236,736 
Total        $-   $236,736 

 

Name of Related Party  Relationship  Nature 

For the Nine Months Ended

September 30, 2020

  

For the Nine Months Ended

September 30, 2019

 
               
SEA  VIE of ASL, Mr. How Kok Choong, the CEO and director of the Company is the sole shareholder and director of SEA  Sales of products  $-   $1,076,044 
Agape Superior Living Pty Ltd (“ASLPL”)  Mr. How Kok Choong, the CEO and director of the Company is a 51% shareholder and a director of ASLPL  Sales of products   13,654    21,461 
Total        $13,654   $1,097,505 

 

Other income

 

Name of Related Party  Relationship  Nature 

For the Three Months Ended

September 30, 2020

  

For the Three Months Ended

September 30, 2019

 
               
Hostastay Sdn. Bhd.  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay  Sublease rental income due from Hostastay  $1,443   $- 
Total        $1,443   $- 

 

Name of Related Party  Relationship  Nature 

For the Nine Months Ended

September 30, 2020

  

For the Nine Months Ended

September 30, 2019

 
               
Hostastay Sdn. Bhd.  Mr. How Kok Choong, the CEO and director of the Company is also the director of Hostastay  Sublease rental income due from Hostastay   1,443    - 
Total        $1,443   $- 

 

F-26

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

15. STOCKHOLDERS’ EQUITY

 

Preferred stock

 

As of September 30, 2020, and December 31, 2019, there were 200,000,000 preferred stocks authorized but none were issued and outstanding.

 

Common stock

 

As of September 30, 2020, and December 31, 2019, there were 1,000,000,000 common stocks authorized, 376,452,047 and 376,275,500 shares issued and outstanding, respectively.

 

In May 2020, the Company issued 162,694 shares of the Company’s common stock in connection with the acquisition of ASL as part of the acquisition payment.

 

In June 2020, ASL made certain adjustments to its March 31, 2020 financial statements. As a result, the net assets carrying value increased by $90,043, which required the issuance of an additional 13,853 shares of the Company’s common stock to fully satisfy the acquisition payment for ASL to Mr. How Kok Choong, CEO and director of the Company. The 13,853 additional shares were issued in July 2020.

 

There were no stock options, warrants or other potentially dilutive securities outstanding as of September 30, 2020 and December 31, 2019.

 

Non-controlling interest

 

As of September 30, 2020 and for the three and nine months ended September 30, 2020, no material transactions of non-controlling interest occurred from the operating results from ASL as the Company holds approximately 99.99% of the equity interest in ASL, non-controlling interests that present in ASL is $0 and therefore not presented separately in the accompanying unaudited condensed consolidated financial statements.

 

16. INCOME TAXES

 

The United States and foreign components of income (loss) before income taxes were comprised of the following:

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2020   2019   2020   2019 
                 
Tax jurisdictions from:                    
Local  $(96,606)  $(86,056)  $(400,776)  $(128,388)
- Foreign – Malaysia   719,561    (22,072)   1,033,341    20,727 
- Foreign – Hong Kong   (149,977)   10,064    (170,030)   (374,564)
Income (loss) before income tax  $472,978   $(98,064)  $462,535   $(482,225)

 

F-27

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

The (provision for) benefit of income taxes consisted of the following:

 

  

For the Three Months Ended

September 30,
2020

  

For the Three Months Ended

September 30,
2019

  

For the Nine Months Ended

September 30,
2020

  

For the Nine Months Ended

September 30,
2019

 
                 
Current:                    
- Local  $-   $-   $-   $- 
- Foreign   (20,381)   -    (20,381)   6,965 
                     
Deferred:                    
- Local   -    -    -    - 
- Foreign   (37,560)   -    (171,627)   - 
                     
(Provision for) benefit of income taxes  $(57,941)  $-   $(192,008)  $6,965 

 

The effective tax rate in the periods presented is the result of the mix of income earned in various tax jurisdictions that apply a broad range of income tax rates. The Company and its subsidiary that operate in various countries: United States, Malaysia (including Labuan) and Hong Kong that are subject to taxes in the jurisdictions in which they operate, as follows:

 

United States of America

 

Agape ATP Corporation was incorporated in the State of Nevada and is subject to the tax laws of the United States of America. As of September 30, 2020, the operations in the United States of America incurred approximately $607,000 of cumulative net operating losses which can be carried forward to offset future taxable income. Approximately $10,000 and $24,000 of the net operating loss carry forwards will expire in 2027 and 2028, respectively, if unutilized. The remaining balance can be carried forward indefinitely. The deferred tax valuation allowance as of September 30, 2020 and December 31, 2019 were approximately $128,000 and $43,000, respectively.

 

Malaysia

 

Changes to the Labuan Business Activity Tax Act (LBATA) 1990 which was gazetted and came into operation on January 1, 2019 mandate companies incorporated in Labuan to satisfy the “substantial activity requirements” to qualify for the preferential tax rate of 3% on net audited profit. Subsequently, on April 29, 2020, a circular setting out revisions to the “substantial activity requirements” was issued. As Agape ATP Corporation does not maintain a permanent establishment in Labuan, the company is subject to tax at 24% on its net audited profit until such a time it satisfies the said requirements.

 

F-28

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

16. INCOME TAXES (Continued)

 

Agape Superior Living Sdn Bhd, Agape S.E.A Sdn Bhd and Wellness ATP International Holdings sdn Bhd. are governed by the income tax laws of Malaysia and the income tax provision in respect of operations in Malaysia is calculated at the applicable tax rates on the taxable income for the periods based on existing legislation, interpretations and practices in respect thereof. Under the Income Tax Act of Malaysia, enterprises that incorporated in Malaysia are usually subject to a unified 24% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption may be granted on case-by-case basis. The tax rate for small and medium sized companies (generally companies incorporated in Malaysia with paid-in capital of RM 2,500,000 or less) is 17% for the first RM 600,000 (or approximately $150,000) for the three and nine months ended September 30, 2020 and RM 500,000 (or approximately $125,000) income for the three and nine months ended September 30, 2019, with the remaining balance being taxed at the 24% rate.

 

Hong Kong

 

Agape ATP International Holding (HK) Limited is subject to Hong Kong Profits Tax, which is charged at the statutory income rate of 16.5% on its assessable income derived from Hong Kong. Business income derived or business expenses incurred outside the Special Administrative Region is not subject to Hong Kong Profits Tax or deduction.

 

The following table sets forth the significant components of the aggregate deferred tax assets of the Company as of:

 

  

As of

September 30, 2020

  

As of

December 31, 2019

 
         
Deferred tax assets:          
Net operating loss carry forwards in U.S.  $127,573   $43,410 
Net operating loss carry forwards in Malaysia   66,109    - 
Less: valuation allowance   (127,573)   (43,410)
Deferred tax liabilities:          
Depreciation   (66,109)   - 
Deferred tax assets, net  $-   $- 

 

Uncertain tax positions

 

The Company evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of September 30, 2020, and December 31, 2019, the Company did not have any significant unrecognized uncertain tax positions. The Company did not incur interest and penalties tax for the three and nine months ended September 30, 2020 and 2019.

 

F-29

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

17. CONCENTRATIONS OF RISKS

 

(a) Major customers

 

For the three and nine months ended September 30, 2020, no customer accounted for 10% or more of the Company’s total revenues. For the three months ended September 30, 2019, one related party customer accounted for approximately 100.0% of the Company’s total revenues. For the nine months ended September 30, 2019, one related party customer accounted for approximately 98.0% of the Company’s total revenues.

 

As of September 30, 2020, receivables from a third-party e-commerce company accounted for approximately 99.5% of the total balance of accounts receivable. As of December 31, 2019, one related party customer accounted for 100.0% of the total balance of accounts receivable.

 

(b) Major vendors

 

For the three months ended September 30, 2020, two vendor accounted for approximately 63.7% and 36.3% of the Company’s total purchases. For the nine months ended September 30, 2020, two vendor accounted for approximately 66.6% and 33.4% of the Company’s total purchases. For the three months ended September 30, 2019, one vendors accounted for 100.0% of the Company’s total purchases, respectively. For the nine months ended September 30, 2019, two vendors accounted for approximately 69.0% and 31.0% of the Company’s total purchases, respectively.

 

There are no accounts payable balance as of September 30, 2020. As of December 31, 2019, one vendor accounted for 100% of the total balance of accounts payable.

 

(c) Commission Expenses to Sales Distributors and Stockists

 

For the three months ended September 30, 2020, two sales distributors accounted for approximately 10.5% and 10.3% of the Company’s total commission expense. For the nine months ended September 30, 2020, no sales distributor accounted for 10% or more of the Company’s total commission expense.

 

(d) Credit risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. As of September 30, 2020, and December 31, 2019, $756,707 and $238,937 were deposited with financial institutions, respectively, $276,769 and $0 of these balances are not covered by deposit insurance. While management believes that these financial institutions are of high credit quality, it also continually monitors their credit worthiness.

 

Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its account receivable is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Historically, the Company did not have any bad debt on its account receivable.

 

(e) Exchange rate risk

 

The Company cannot guarantee that the current exchange rate will remain steady; therefore, there is a possibility that the Company could post the same amount of profit for two comparable periods and because of the fluctuating exchange rate actually post higher or lower profit depending on exchange rate of RM and HK$ converted to US$ on that date. The exchange rate could fluctuate depending on changes in political and economic environments without notice.

 

F-30

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES

 

Lease commitments

 

On April 1, 2020, the Company adopted ASC 842 for ASL’s office space lease and sales and training center as the lease commencement date upon the acquisition of ASL. The Company recognized lease liabilities of approximately $489,000, with a corresponding right-of-use (“ROU”) asset in the same amount based on the present value of the future minimum rental payments of the lease, using an effective interest rate of 5.5%, which was determined using the Company’s estimated incremental borrowing rate. The weighted remaining term of the lease is approximately 2.79 years.

 

The five-year maturity of the Company’s operating lease liabilities is as follow:

 

Twelve Months Ending
September 30,
  Operating lease liabilities 
     
2021  $166,524 
2022   163,689 
2023   121,242 
Total lease payments   451,455 
Less: interest   (33,198)
Present value of lease liabilities  $418,257 

 

The Company also leases one distribution center and two employee apartments with an expiring term of twelve months or fewer, which were classified as operating leases. For lease terms of twelve months or fewer, a lessee is permitted to make an accounting policy election not to recognize lease assets and liabilities. The Company selected not to recognize lease assets and liabilities on these leases. As of September 30, 2020, the Company’s commitment for minimum lease payments under these operating leases within the next twelve months are $7,816.

 

Rent expense for the three months ended September 30, 2020 and 2019 was $58,793 and $13,400, respectively. Rent expense for the nine months ended September 30, 2020 and 2019 was $111,465 and $40,166, respectively.

 

Purchase commitments

 

The total future minimum purchase commitment under a non-cancellable purchase contract as of September 30, 2020 for the next five years and thereafter is as follows:

 

Twelve months ending September 30, 

Minimum

purchase

 
2021  $693,900 
2022   693,900 
2023   693,900 
2024   693,900 
2025   693,900 
Thereafter   1,561,275 
Total minimum purchase commitments required  $5,030,775 

 

F-31

 

 

AGAPE ATP CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(Currency expressed in United States Dollars (“US$”), except for number of shares)

 

18. COMMITMENTS AND CONTINGENCIES (Continued)

 

As of the date of this report, the Company’s vendor is not able to meet the Company’s minimum purchase commitment of the health and wellness products due to the manufacturing process was being delayed by its vendor.

 

Contingencies

 

Legal

 

From time to time, the Company is party to certain legal proceedings, as well as certain asserted and un-asserted claims. Amounts accrued, as well as the total amount of reasonably possible losses with respect to such matters, individually and in the aggregate, are not deemed to be material to the consolidated financial statements.

 

COVID-19

 

On March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic. In accordance with the recommendations of the WHO, Malaysia had imposed a nationwide lockdown via the government’s Movement Control Order (“MCO”) effective March 18, 2020. The MCO has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. On May 4, 2020, the MCO was lessened to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia.

 

Substantially all of the Company’s revenues are concentrated in Malaysia. Consequently, its results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to its results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond its control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of the Company’s customers or suspension supplies may negatively affected, and could continue to negatively affect, the demand for the Company’s product;
  the Company may have to provide significant sales incentives to its customers during the outbreak, which may in turn materially adversely affect its financial condition and operating results; and

 

any disruption of the Company’s supply chain, logistics providers or customers could adversely impact its business and results of operations, including causing the Company or its suppliers to cease manufacturing for a period of time or materially delay delivery to its customers, which may also lead to loss of its customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that the Company’s total revenues will grow or remain at the similar level year over year in the remaining period of 2020 and in 2021.

 

F-32

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this quarter report on Form 10-Q is intended to update the information contained in our Form 10-K, dated March 27, 2020, for the six months ended December 31, 2019 and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in such Form 10-K. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Form 10-Q.

 

The following discussion contains certain statements that may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements appear in a number of places in this Report, including, without limitation, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are not guarantees of future performance and involve risks, uncertainties and requirements that are difficult to predict or are beyond our control. Forward-looking statements speak only as of the date of this quarterly report. You should not put undue reliance on any forward-looking statements. We assume no responsibility to update the forward-looking statements contained in this transition report on Form 10-Q. The following should also be read in conjunction with the unaudited condensed Consolidated Financial Statements and notes thereto that appear elsewhere in this report.

 

Company Overview

 

Agape ATP Corporation, a Nevada corporation (“the Company”) was incorporated under the laws of the State of Nevada on June 1, 2016.

 

Agape ATP Corporation operates through its wholly owned subsidiary, Agape ATP Corporation, a Company organized in Labuan, Malaysia.

 

Agape ATP Corporation, incorporated in Labuan, Malaysia, is an investment holding company with 100% equity interest in Agape ATP International Holding Limited, a company incorporated in Hong Kong.

 

On May 8, 2020, the Company entered into a Share Exchange Agreement with Mr. How Kok Choong, CEO and director of the Company to acquire 9,590,596 ordinary shares, no par value, equivalent to approximately 99.99% of the equity interest in Agape Superior Living Sdn. Bhd., an entity incorporated in Malaysia.

 

Agape Superior Living Sdn. Bhd. (“ASL”) is a limited company incorporated on August 8, 2003, under the laws of Malaysia.

 

On September 11, 2020, the Company incorporated Wellness ATP International Holdings Sdn, Bhd. (“WATP”), a wholly owned subsidiary under the laws of Malaysia, to pursue the business of promoting wellness and wellbeing lifestyle of the community by providing services that includes online editorials, programs, events and campaigns on how to achieve positive wellness and lifestyle. On September 15, 2020, WATP entered into a business collaboration agreement with ASL to carry out certain wellness programs.

 

The Company and its subsidiaries are principally engaged in the Health and Wellness Industry. The principal activity of the Company is to supply high-quality health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging and products designed to improve the overall health system of the human body and various wellness programs.

 

Agape ATP Corporation is a company that provides health and wellness products and health solution advisory services to our clients. The Company primarily focus its efforts on attracting customers in Malaysia. Its advisory services center on the “ATP Zeta Health Program”, which is a health program designed to effectively prevent diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles, and promotion of health. The program aims to promote improved health and longevity in our clients through a combination of modern medicine, proper nutrition and advice from skilled nutritionists and/or dieticians.

 

In order to strengthen the Company’s supply chain, on May 8, 2020, the Company has successfully acquired approximately 99.99% of ASL, with the goal of securing an established network marketing sales channel that has been established in Malaysia for the past 15 years. ASL has been offering the Company’s ATP Zeta Health Program as part of its product lineup. As such, the acquisition creates synergy in the Company’s operation by boosting the Company’s retail and marketing capabilities. The newly acquired subsidiary allows the Company to fulfill its mission of “helping people to create health and wealth” by providing a financially rewarding business opportunity to distributors and quality products to distributors and customers who seek a healthy lifestyle.

 

The Company deems creating public awareness on wellness and wellbeing lifestyle as essential to enhance the provision of its health solution advisory services; and therefore incorporated WATP. Upon its establishment, WATP started collaborating with ASL to carry out various wellness programs.

 

The Company offers three series of programs which consist of different services and products: ATP Zeta Health Program, ÉNERGÉTIQUE and BEAUNIQUE.

 

The ATP Zeta Health Program is a health program designed to promote health and general wellbeing designed to prevent health diseases caused by polluted environments, unhealthy dietary intake and unhealthy lifestyles. The program aims to promote improved health and longevity through a combination of modern health supplements, proper nutrition and advice from skilled dieticians as well as trained members and distributors.

 

The ÉNERGÉTIQUE series aims to provide a total dermal solution for a healthy skin beginning from the cellular level. The series is comprised of the Energy Mask series, Hyaluronic Acid Serum and Mousse Facial Cleanser.

 

The BEAUNIQUE product series focuses on the research of our diet’s impact on modifying gene expressions in order to address genetic variations and deliver a nutrigenomic solution for every individual.

 

3

 

 

Results of Operation

 

For the three months ended September 30, 2020 and 2019

 

Revenue

 

The Company generated revenue of $1,413,063 for the three months ended September 30, 2020 as compared to $236,736 for the three months ended September 30, 2019, a significant increase of $1,176,327 or approximately 496.9%. The revenue was mainly derived from the increased sale of health and wellness products as a result of the operation of ASL, which brought us to a large group of customers in an established network marketing sales channel that has been established in Malaysia for the past 15 years. For the three months ended September 30, 2019, we were only making sales to our related party on a wholesale basis when they placed the purchase orders.

 

Cost of Revenue

 

Cost of revenue for the three months ended September 30, 2020 amounted to $186,891 as compared to $210,383 for the three months ended September 30, 2019, a decrease of $23,492 or approximately 11.2%. The cost of revenue consist of cost of goods and packing materials. The cost of revenue for the current reporting period was predominately incurred by ASL for its retail activities, while the cost of revenue for the corresponding period last year was related to wholesale business of the Company prior to the acquisition of ASL.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2020 amounted to $1,226,172 as compared to $26,353 for the three months ended June 30, 2019, a significant increase of $1,199,819 or approximately 4,552.9%. Gross margin for the three months ended September 30, 2020 was approximately 86.8% as compared to approximately 11.1% for the three months ended September 30, 2019. The increase in gross profit was predominately due to the increase in revenue as a result from the operation of ASL, which brought us to a large group of customers in an established network marketing sales channel as compared to the three months ended September 30, 2019, which we generated lower gross margins from our sales to our related party wholesales customer.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses and general and administrative expenses.

 

Selling expenses

 

Selling expenses for the three months ended September 30, 2020 amounted to $159,292 as compared to $338 for the three months ended September 30, 2019, a significant increase of $158,954 or approximately 47,027.8%. The significant increase was predominately due to the operation of ASL which contributed additional selling expenses to our operations and an increase of approximately $85,000 of salary and employee benefit expenses of our employees in ASL’s sales center for the three months ended September 30, 2020. As compared to the same period in 2019, we did not have any employees in our sales team. The significant increase was also attributable to the increase of approximately $16,000 of credit card charges of processing sales transactions from our customers, the increase of approximately $34,000 of promotional and event expenses as we have more events and gifts to promote our products and the increase of other miscellaneous selling expenses of approximately $24,000.

 

Commission expenses

 

Commission expenses were $300,957 and $0 for the three months ended September 30, 2020 and 2019, respectively, a significant increase of $300,957 or 100.0%. The significant increase in commission expenses was due to the operation of ASL which brought us to a new marketing channel which pay commissions to distributors and members in network sales marketing.

 

4

 

 

General and administrative expenses

 

General and administrative (“G&A”) expenses for the three months ended September 30, 2020 amounted to $355,274, as compared to $102,844 for the three months ended September 30, 2019, a significant increase of $252,430 or approximately 245.4%. The significant increase was predominately due to the increase of salary and employee benefit expenses of approximately $143,000 as we have more employees from the operation of ASL in the three months ended September 30, 2020. The significant increase of G&A expenses was also attributable to the operation of ASL with approximately $109,000 additional general and administrative expenses to our operations, which mainly comprised of rental expenses, professional expenses and depreciation expenses.

 

Other Income (Expenses), Net

 

For the three months ended September 30, 2020, we recorded an amount of $62,329 as other income, net as compared to $21,235 other expenses, net for the three months ended September 30, 2019, an increase of $83,564 or approximately 393.5%. The net other income of $86,748 incurred during the three months ended September 30, 2020 comprised foreign currency exchange gain of $65,307, other income of $12,144, interest income of $9,297, and unrealized holding loss on marketable securities of $24,419 compared to the net other expenses of $21,235 during the three months ended September 30, 2019.

 

Provision for Income Taxes

 

The Company recorded provision for income taxes of $57,941 and $0 for the three months ended September 30, 2020 and 2019, respectively. During the three months ended September 30, 2020, we generated taxable income in ASL that is subjected to a unified 24% income tax rate.

 

Net Income (Loss)

 

Net income increased by $513,101 from net loss of $98,064 for the three months ended September 30, 2019 to net income of $415,037 for the three months ended September 30, 2020, mainly due to reasons as discussed above.

 

For the nine months ended September 30, 2020 and 2019

 

Revenue

 

The Company generated revenue of $2,936,925 for the nine months ended September 30, 2020 as compared to $1,097,505 for the nine months ended September 30, 2019, a significant increase of $1,839,420 or approximately 167.6%. The revenue was predominately derived from the increased sales of health and wellness products as a result from the acquisition of ASL, which brought us to a large group of customers in an established network marketing sales channel that has been in established in Malaysia for the past 15 years. For the nine months ended September 30, 2019, we were only making sales to our related party on wholesale basis when they placed the purchase orders.

 

Cost of Revenue

 

Cost of revenue for the nine months ended September 30, 2020 amounted to $658,445 as compared to $1,027,733 for the nine months ended September 30, 2019, a decrease of $369,288 or approximately 35.9%. The cost of revenue was consist of cost of goods purchased and packing materials. The cost of revenue for the current reporting period was predominately incurred by ASL for its retail activities, while the cost of revenue for the corresponding period last year was related to wholesale business of the Company prior to the acquisition of ASL.

 

5

 

 

Gross Profit

 

Gross profit for the nine months ended September 30, 2020 amounted to $2,278,480 as compared to $69,772 for the nine months ended September 30, 2019, a significant increase of $2,208,708 or approximately 3,165.6%. Gross margin for the nine months ended September 30, 2020 was approximately 77.6% as compared to approximately 6.4% for the nine months ended September 30, 2019. The increase of gross margin was predominately due to the increase of revenue and decrease in cost of revenue for the nine months ended September 30, 2020 as compared to the same period in 2019 as a result from the acquisition of ASL, which brought us to a large group of customers in an established network marketing sales channel. For the nine months ended September 30, 2020, we generated higher gross margins of selling our products directly to the customers in the network channel as compared to the nine months ended September 30, 2019, which we generated a much lower gross margins from our sales to our related party wholesales customer.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, commission expenses and general and administrative expenses.

 

Selling expenses

 

Selling expenses for nine months ended September 30, 2020 amounted to $268,648 as compared to $8,184 for the nine months ended September 30, 2019, a significant increase of $260,464 or approximately 3,182.6%. The significant increase was predominately due to the acquisition of ASL which attributed additional selling expenses to our operations and resulted from the increase of approximately $170,000 salary and employee benefit expenses of our employees in ASL’s sales center for the nine months ended September 30, 2020. As compared to the same period in 2019, we did not have any employees in our sales team. The significant increase was also attributable to the increase of approximately $25,000 credit card charges of processing sales transactions from our customers, the increase of approximately $36,000 of promotional and event expenses as we have more events and gifts to promote our products and the increase of other miscellaneous selling expenses of approximately $30,000.

 

Commission expenses

 

Commission expenses were $683,455 and $0 for the nine months ended September 30, 2020 and 2019, respectively, a significant increase of $683,455 or 100.0%. The significant increase in commission expenses was due to the acquisition of ASL which brought us to a new marketing channel which pays commissions to distributors and members in network sales marketing.

 

General and administrative expenses

 

General and administrative expenses for the nine months ended September 30, 2020 amounted to $1,029,052, as compared to $186,622 for the nine months ended September 30, 2019, a significant increase of $842,430 or approximately 451.4%. The significant increase was predominately due to the increase of professional fees of approximately $349,000 as we have recently hired new professional firms located in the U.S. and Hong Kong, including legal counsel, auditor, and financial reporting consultant, to strengthen our current Securities and Exchange Commission (“SEC”) listing reporting documents and to continue to stay compliant and professional services incurred in relation to the acquisition of ASL during the nine months ended September 30, 2020 as compared to the same period in 2019, we were using local professional firms in Malaysia. Professional fee incurred by the U.S. and Hong Kong firms are generally higher than the professional fees incurred by the Malaysia firms. The significant increase of G&A expenses was also attributable to the acquisition of ASL with approximately $459,000 additional general and administrative expenses to our operations, which mainly comprised of rental expenses, salary and employee benefit expenses and depreciation expenses. In addition, the increase of G&A expenses was also due to the increase of approximately $34,000 of travelling expenses for our CEO for potential business developments.

 

6

 

 

Other Income (Expenses), Net

 

For the nine months ended September 30, 2020, we recorded an amount of $165,210 as other income, net as compared to $357,191 other expenses, net for the nine months ended September 30, 2019, a significant increase of $522,401 or approximately 146.3%. The net other income of $165,210 incurred during the nine months ended September 30, 2020 comprised of interest income of $41,230, other income of $29,738, foreign currency loss of $8,005 and unrealized holding gain on marketable securities of $102,247. The net other expenses of $357,191 incurred during the nine months ended September 30, 2019 comprised other income of $19,219, $26,085 on share of loss in investee company from our equity investment, $16,509 on gain on deemed disposal of shares in investee company and $366,834 of impairment loss in our equity investment.

 

Provision for (Benefit of) Income Taxes

 

The Company recorded provision for (benefit of) income taxes $192,008 and $(6,965) for the nine months ended September 30, 2020 and 2019, respectively. During the nine months ended September 30, 2020, we generated taxable income in ASL that are subject to a unified 24% income tax rate. On the other hand, during the nine months ended September 30, 2019, we incurred taxable losses that can be carried forward for 7 years, which resulted in recognition of deferred tax assets on net operating loss and income tax benefits.

 

Net Income (Loss)

 

Net income increased by $745,787 from net loss of $475,260 for the nine months ended September 30, 2019 to $270,527 for the nine months ended September 30, 2020, predominately due to reasons as discussed above.

 

Liquidity and Capital Resources

 

On March 11, 2020, the World Health Organization or WHO declared the corona virus or COVID-19 a pandemic.

To help counter the transmission of COVID-19, the government of Malaysia initiated movement control orders (“MCO”), the first effective March 18, 2020. The MCO had resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in Malaysia. The first MCO was extended three times, each for a two-weeks period, until May 12, 2020. On May 13, 2020, the MCO was eased to a Conditional Movement Control Order (“CMCO”) where most business sectors were allowed to operate under strict rules and Standard Operating Procedures mandated by the government of Malaysia. The CMCO was further relaxed, and on June 8, 2020, Malaysia moved into the Recovery Movement Control Order (“RMCO”). Due to a resurgence of COVID-19, CMCO was reimposed in the state of Sabah, Selangor, Kuala Lumpur and Putrajaya effective October 14, 2020. On November 7, 2020, the CMCO was extended to a wider geographical area to include another six states in the country. Effectively, ten of thirteen states in Malaysia were placed under CMCO with the exceptions of Perlis, Pahang and Kelantan.

 

Substantially all of our revenues are concentrated in Malaysia. Consequently, our results of operations will likely be adversely, and may be materially, affected, to the extent that the COVID-19 or any other epidemic harms the Malaysia and global economy in general. Any potential impact to our results will depend on, to a large extent, future developments and new information that may emerge regarding the duration and severity of the COVID-19 and the actions taken by government authorities and other entities to contain the COVID-19 or treat its impact, almost all of which are beyond our control. Potential impacts include, but are not limited to, the following:

 

  temporary closure of offices, travel restrictions, financial impact of our customers or suspension supplies may negatively affected, and could continue to negatively affect, the demand for our products;
  we may have to provide significant sales incentives to our customers during the outbreak, which may in turn materially adversely affect our financial condition and operating results; and
  any disruption of our supply chain, logistics providers or customers could adversely impact our business and results of operations, including causing us or our suppliers to cease manufacturing for a period of time or materially delay delivery to our customers, which may also lead to loss of our customers.

 

Although some of the countries from which our products are sourced are experiencing lockdowns, industries involve in the provision of food especially health products and pharmaceuticals are normally exempted. We may experience slight delay in products delivery lead time but barring unforeseen circumstances, the setback should be temporary.

 

7

 

 

We currently operating primarily in Malaysia and anticipate expanding into the Asian markets in the future, with a particular focus, at least initially, on expanding into Thailand, Indonesia and Taiwan. We will explore expansion via e-commerce. When the pandemic has subsided or is over and restrictions on travelling between nations are uplifted, we will set up offices in the countries in which we operate to better service our customers.

 

Because of the uncertainty surrounding the COVID-19 outbreak, the financial impact related to the outbreak of and response to the COVID-19 cannot be reasonably estimated at this time. There is no guarantee that our total revenues will grow or remain at the similar level year over year in the remaining period of 2020 and in 2021.

 

As of September 30, 2020, we had working capital of $4,926,908 consisting of cash in bank of $756,707 and time deposits of $2,564,672 as compared to working capital of $3,452,665 consisting of cash in bank of $238,937 and time deposits of $2,505,520 as of December 31, 2019. In assessing our liquidity, we monitor and analyze our cash on-hand and our operating expenditure commitments. Our liquidity needs are to meet our working capital requirements and operating expenses obligations. We believe we will have sufficient liquidity to fund our working capital needs for the next 12 months from the date of issuance of this Form 10-Q.

 

The following summarizes the key components of our cash flows for the nine months ended September 30, 2020 and 2019:

 

   For the Nine Months Ended 
   September 30, 2020   September 30, 2019 
         
Net cash used in operating activities  $(743,670)  $(691,672)
Net cash provided by (used in) investing activities   1,276,114    (1,500)
Net cash provided by (used in) financing activities   21,104    (4,573)
Effect of exchange rate on cash and cash equivalents   45,585    (2,092)
Net change in cash and cash equivalents  $599,133   $(699,837)

 

Operating activities

 

Net cash used in operating activities for the nine months ended September 30, 2020 was $743,670and were predominately comprised of the non-cash income on unrealized holding gain on marketable securities of $102,247, the increase of accounts receivables of $271,876, the increase of prepaid taxes of $123,507, the decrease of customer deposits of $1,268,487 and the payment of operating lease liabilities of $69,021. The net cash used in operating activities was mainly offset by the net income of $270,527, the non-cash depreciation and amortization expense of $37,517, amortization of operating right-of-use assets of $70,047, deferred tax provision of $171,586, the decrease in inventories of $132,939, the decrease in prepayments and deposits, including related party of $245,496, and the increase in other payables and accrued liabilities of $167,603.

 

Net cash used in operating activities for the nine months ended September 30, 2019 was $691,672 and were predominately comprised of net loss of $475,260, the non-cash expense of gain on deemed disposal of shares in Investee Company of $16,509, the increase of related party accounts receivable of $550,311, and the decrease in customer deposits of $217,743. The net cash used in operating activities was mainly offset by the non-cash expense of loss from equity investment of $26,085 and the impairment loss in equity investment of $366,834, the decrease of prepayments and deposits of $148,020, and the increase in other payables and accrued liabilities of $36,391.

 

Investing activities

 

Net cash provided by investing activities for the nine months ended September 30, 2020 was $1,276,114, which were in respect of cash and cash equivalents acquired through acquisition of ASL of $1,210,818 and partial proceeds collected from the sale of our non-marketable securities of $70,173, offset by purchase of equipment and intangible assets of $4,877.

 

8

 

 

Net cash used in investing activities for the nine months ended September 30, 2019 was $1,500 which was due to the investment in non-marketable securities.

 

Financing activities

 

Net cash provided by financing activities for the nine months ended September 30, 2020 was $21,104 which were mainly comprised of repayments from related parties of $224,342 offset by payment of deferred offering cost of $203,238.

 

Net cash used in financing activities for the nine months ended September 30, 2019 was $4,573 which were due to the repayment to a director of $5,318 offset by repayment from related parties of $745.

 

Credit Facilities

 

We do not have any credit facilities or other access to bank credit.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2020, we have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

 

Critical Accounting Polices

 

Use of estimates

 

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in the Company’s unaudited condensed consolidated financial statements include allowance for doubtful accounts, allowance for inventories obsolescence, useful lives of property and equipment, useful lives of intangible assets, impairment of long-lived assets, allowance for deferred tax assets, operating right-of-use assets, operating lease liabilities and uncertain tax position and impairment of investment in non-marketable securities. Actual results could differ from these estimates.

 

Revenue recognition

 

On July 1, 2019, the Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) using the modified retrospective method for contracts that were not completed as of June 30, 2019. This did not result in an adjustment to retained earnings upon adoption of this new guidance as the Company’s revenue was recognized based on the amount of consideration expected to receive in exchange for satisfying the performance obligations.

 

The core principle underlying the revenue recognition of this ASU allows the Company to recognize - revenue that represents the transfer of goods and services to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. This will require the Company to identify contractual performance obligations and determine whether revenue should be recognized at a point in time or over time, based on when control of goods and services transfers to a customer. The Company’s revenue streams are recognized at a point in time for the Company’s sale of health and wellness products.

 

9

 

 

The ASU requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation.

 

The Company accounts for a contract with a customer when the contract is committed in writing, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of substantially collection.

 

Prior to July 1, 2019, the Company recognizes revenue from sales of goods when the following four revenue criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) selling price is fixed or determinable; and (4) collectability is reasonably assured. Revenue from supplies of health and wellness products is recognized when title and risk of loss are transferred and there are no continuing obligations to the customer. Title and the risks and rewards of ownership transfer to and accepted by the customer when the products are collected by the customer at the Company’s office. Revenue is recorded net of sales discounts, returns, allowances, and other adjustments that are based upon management’s best estimates and historical experience and are provided for in the same period as the related revenues are recorded.

 

The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue. Upon adoption on July 1, 2019, the Company evaluated its revenue recognition policy for all revenue streams within the scope of the ASU under previous standards and using the five-step model under the new guidance and confirmed that there were no differences in the pattern of revenue recognition.

 

Sales of Health and Wellness products

 

- Performance obligations satisfied at a point in time

 

On July 1, 2019, the Company derives its revenues from sales contracts with its customers with revenues being recognized when control of the health and wellness products are transferred to its customer at the Company’s office or shipment of the goods, which is generally similar to when its delivery has occurred prior to July 1, 2019 Such revenues are recognized at a point in time after all performance obligations are satisfied. The revenue is recorded net of estimated discounts and return allowances. Products are given 60 days for returns or exchanges from the date of purchase. Historically, there were insignificant sales returns.

 

The Company also sells coupons to its customers for cash at a discounted price of the value of the coupons. Customers can apply the value of the coupons for a reduction in the transaction price paid by the customer are recorded as a reduction of sales. The cash proceeds resulted from the sale of coupons are recognized as customer deposits until the coupons to be applied as a reduction of the health and wellness products transaction price upon such sales transactions occurred. The Company’s coupons have a validity period of six months. If the Company’s customers did not utilized the coupons after six months, the Company would recognize the forfeiture of the originated sales value of the coupons as net revenues.

 

10

 

 

Sales of Health and Wellness services

 

- Performance obligations satisfied at a point in time

 

The Company carries out its Wellness program, where the Company’s products are bundled with health screening test and a health camp program. The health screening test and the health camp programs are considered as separate performance obligations. The promises to deliver the health screening test report and the attendance at the health camp are separately identifiable, which are evidenced by the fact that the Company provides separate services of delivering the health screening test report and allowing admission of the customers to attend the health camp. The Company derives its revenues from sales contracts with its customers with revenues being recognized when the test reports are completed and delivered to its customers.

 

The Company also separately derives its revenues from sales contracts with its customers with revenues being recognized when the health camp program was completed in the final day of the health camp. For the three and nine months ended September 30, 2020, revenues from health and wellness services are immaterial to the Company’s unaudited condensed consolidated statements of operations and comprehensive income (loss).

 

Fair value of financial instruments

 

The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company.

 

The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
  Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

 

Financial instruments included in current assets and current liabilities are reported in the consolidated balance sheets at face value or cost, which approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest.

 

Recent accounting pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of such any pronouncements may be expected to cause a material impact on its financial condition or the results of its operations, as follow:

 

11

 

 

In May 2019, the FASB issued ASU 2019-05, which is an update to ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced the expected credit losses methodology for the measurement of credit losses on financial assets measured at amortized cost basis, replacing the previous incurred loss methodology. The amendments in Update 2016-13 added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. Update 2016-13 also modified the accounting for available-for-sale debt securities, which must be individually assessed for credit losses when fair value is less than the amortized cost basis, in accordance with Subtopic 326-30, Financial Instruments— Credit Losses—Available-for-Sale Debt Securities. The amendments in this Update address those stakeholders’ concerns by providing an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. For those entities, the targeted transition relief will increase comparability of financial statement information by providing an option to align measurement methodologies for similar financial assets. Furthermore, the targeted transition relief also may reduce the costs for some entities to comply with the amendments in Update 2016-13 while still providing financial statement users with decision-useful information. In November 2019, the FASB issued ASU No. 2019-10, which to update the effective date of ASU No. 2016-13 for private companies, not-for-profit organizations and certain smaller reporting companies applying for credit losses, leases, and hedging standard. The new effective date for these preparers is for fiscal years beginning after December 15, 2022. ASU 2019-05 is effective for the Company for annual and interim reporting periods beginning January 1, 2023 as the Company is qualified as a smaller reporting company. The Company is currently evaluating the impact ASU 2019-05 may have on its unaudited condensed consolidated financial statements.

 

In January 2020, the FASB issued ASU 2020-01 to clarify the interaction of the accounting for equity securities under ASC 321 and investments accounted for under the equity method of accounting in ASC 323 and the accounting for certain forward contracts and purchased options accounted for under ASC 815. With respect to the interactions between ASC 321 and ASC 323, the amendments clarify that an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting when applying the measurement alternative in ASC 321, immediately before applying or upon discontinuing the equity method of accounting. With respect to forward contracts or purchased options to purchase securities, the amendments clarify that when applying the guidance in ASC 815-10-15-141(a), an entity should not consider whether upon the settlement of the forward contract or exercise of the purchased option, individually or with existing investments, the underlying securities would be accounted for under the equity method in ASC 323 or the fair value option in accordance with ASC 825. The ASU is effective for interim and annual reporting periods beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company does not expect the adoption of this standard to have a material impact on its unaudited condensed consolidated financial statements.

 

12

 

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Foreign exchange risk. Substantially most of our revenues are denominated in the U.S. dollar while most of our expenses are denominated in Malaysian Ringgit and Hong Kong Dollar. We do not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign currencies or any other derivative financial instruments. Although in general, our exposure to foreign exchange risks should be limited, the value of an investment in our Common Stock may be affected by the foreign exchange rate between U.S. dollar and Malaysian Ringgit; and U.S. dollar and Hong Kong Dollar because the value of our business is effectively denominated in Malaysian Ringgit and Hong Kong Dollar, while the Common Stock is traded in U.S. dollars.

 

Credit risk. Financial instruments that are potentially subject to credit risk consist principally of accounts receivable. The Company believes the concentration of credit risk in its trade receivables is substantially mitigated by its ongoing credit evaluation process and relatively short collection terms. The Company does not generally require collateral from customers. The Company evaluates the need for an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures:

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2020. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer. Based upon that evaluation, our Chief Executive Officer concluded that, as of September 30, 2020, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of September 30, 2020, our disclosure controls and procedures were not effective:

 

(1) The Company did not have sufficient full-time personnel with appropriate levels of accounting knowledge and experience to monitor the daily recording of transactions, address complex U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP.
   
(2) Lack of a functional internal audit department or personnel that monitors the consistencies of the preventive internal control procedures; lack of adequate policies and procedures in internal audit function to ensure that the Company’s policies and procedures have been carried out as planned.
   
(3) We do not have adequate segregation of duties and effective risk assessment. Lack of segregation of duties and effective risk assessment may cause the Company to face the likelihood of fraud or theft, due to poor oversight, governance and review to detect errors.

 

Management’s Remediation Initiatives

 

In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we will prepare written policies and procedures for accounting and financial reporting with respect to the requirements and application of both U.S. GAAP and SEC guidelines, to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity and debt transactions.

 

We plan to initiate the following series of measures to further strengthen the Company’s internal controls going forward:

 

1. We intend to engage an external consulting firm to supplement our efforts to the implementation of the 2013 Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework for internal controls.
   
2. We intend to establish an internal audit function with assessment of Sarbanes-Oxley compliance requirements and improvement of overall internal control.
   
3. Once we hire additional employees, we intend to initiate a comprehensive program and development plan to provide ongoing company-wide trainings regarding internal control, with particular emphasis on our accounting staff.

 

We anticipate that these initiatives will be at least partially, if not fully, implemented by the end of fiscal year 2020.

 

Changes in Internal Control over Financial Reporting:

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

13

 

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no materials, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest averse to us.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

14

 

 

ITEM 6. Exhibits

 

Exhibit No.   Description
     
31.1   Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer*
     
32.1   Section 1350 Certification of principal executive officer *
     
101.INS   XBRL Instance Document*
     
101.SCH   XBRL Schema Document*
     
101.CAL   XBRL Calculation Linkbase Document*
     
101.DEF   XBRL Definition Linkbase Document*
     
101.LAB   XBRL Label Linkbase Document*
     
101.PRE   XBRL Presentation Linkbase Document*

 

* Filed herewith.

 

15

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AGAPE ATP CORPORATION
  (Name of Registrant)
     
Date: November 16, 2020    
  By: /s/ How Kok Choong
  Title:

Chief Executive Officer,

President, Director, Secretary and Treasurer

    (Principal Executive Officer and Principal Accounting Officer)

 

16